



Institut Pasteur Shanghai announces the creation of its global biotech accelerator Advance BioChina

Biovision, Lyon, France - 29 March 2011: Institut Pasteur of Shanghai announces today the creation of its global biotech accelerator company Advance BioChina.

Advance BioChina is an R&D-focused for-profit organization that positions itself as the gateway to China for global biotech companies. Advance BioChina co-invests with global biotech companies into Shanghai-based Joint Ventures to develop high-value China-relevant R&D programs. Advance BioChina will incubate and accompany up to 25 companies over the next 5 years.

Advance BioChina's founder Institut Pasteur of Shanghai (IPS) was established by the Chinese Academy of Sciences, Institut Pasteur and the Shanghai Municipal Government in 2004 and is a legally independent non-profit research organization.

Ralf Altmeyer, Director General of IPS, *"The global pharma industry is investing massively into R&D operations in China while biotech has been lagging behind. Advance BioChina will invest into JVs with global biotech companies and help them develop innovative products for the Chinese and global markets. Biotech companies will benefit from our experience in China, our scientific expertise and technology platforms to achieve their product development goals."*

Alice Dautry, Director General of Institut Pasteur Paris, *"Institut Pasteur has a long history of translating excellence science into applications. The launch of ABC arrives at the right time when we are more than determined to extend our scientific expertise and research applied to public health needs through our unique international and Asian networks."*

China's pharma market has grown 15-20% p.a. over the last 8 years and is forecast to become the world's second largest biggest pharma market by 2020. The healthcare and IP-law reforms in China are improving the R&D environment and commercial perspectives for differentiated medical products.

Zhu Zhiyuan, Executive Director of the Chinese Academy of Sciences Shanghai Branch, *"There is a significant unmet medical need in all major diseases in China with huge patient pools. Advance BioChina capitalizes on the great quality of science at IPS and its network with other life science institutes at the Chinese Academy of Sciences"*.

Advance BioChina provides access to funding and full incubation services paying special attention to secure the Intellectual Property of its JV partners.

About Institut Pasteur Shanghai

Institut Pasteur Shanghai (IPS) is a legally non-profit research organization established in 2004 to address health issues in China and the Asian region. IPS creates synergies between the Institut Pasteur and the Chinese Academy networks, leveraging all the assets of Shanghai as one of the Asia leading business and technology hubs. IPS is engaged in active research in therapeutics, vaccines, diagnostics and medical devices and in a broad range of infectious diseases programs such as hepatitis, HIV, respiratory infections as well as virus-induced cancer.

IPS is now strong of more than 200 staff and will grow up to 400 staff within the next 3 years.

About BioVision

For over 10 years, BioVision, the World Life Sciences Forum, has been engaging key international leaders from different backgrounds in debates on global issues involving science and society. Every other year in Lyon, BioVision brings together government and business leaders, scholars, policy makers and NGO directors. Participants analyze scientific breakthroughs, pressing global challenges, discuss the most effective solutions, and build lasting partnerships that enable them to create positive social change.

###

Advance BioChina www.advancebiochina.com

Media relations contactus@advancebiochina.com

